Silex Systems (ASX:SLX) announced the U.S. Department of Energy released the Request for Proposal
Silex Systems (ASX:SLX) announced the U.S. Department of Energy released the Request for Proposal for acquisition of High Assay Low Enriched Uranium. As a leader in laser uranium enrichment, management believes its eligible for part of the ~US$600m in funding up for grabs | https://announcements.asx.com.au/asxpdf/20240110/pdf/05z9kyqq248cy1.pdf $SLX #Uranium
Wildcat Resources Limited (ASX:WC8) announces the commencement of exploration activities for 2024
Wildcat Resources Limited (ASX:WC8) announces the commencement of exploration activities for 2024 at its Tabba Tabba Lithium Project. Undertaking this work is a necessary step to allow continued escalation of drilling capability in 2024 https://www.investi.com.au/api/announcements/wc8/f5056b27-51c.pdf #WC8 #lithium ASX:WC8 Share Price [stockdio-historical-chart symbol=”WC8″ stockExchange=”CHIX” width=”580″ height=”380″ motif=”financial” palette=”financial-light”]
Kali Metals (ASX:KM1) commenced trading on the ASX on January 8 2024
Kali Metals (ASX:KM1), an Australian resources company with a portfolio of lithium exploration projects in WA, NSW and VIC, commenced trading on the ASX on January 8 2024. The IPO was heavily oversubscribed and raised the maximum amount of $15 million https://app.sharelinktechnologies.com/announcement/asx/3d096ea12cb3d3e341804735de41e397
NEU Phase 2 trial shows significant improvements
Neuren Pharmaceuticals (ASX:NEU) announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome. Significant improvement was observed by both clinicians and caregivers from treatment | ASX announcement: https://www.neurenpharma.com/pdf/f9ca13b8-b75f-4ff5-a5b7-1dcb75d547d6/P2-trial-shows-significant-improvements-in-PhelanMcDermid.pdf #shorts
NTI Completed patient recruitment for its clinical trial for children with Autism
Neurotech International (ASX:NTI) completed patient recruitment for its Phase II/III NTIASD2 clinical trial for children with Autism. Patients recruited require substantial support and very substantial support autism | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231219/pdf/05yq6fqpsynsvp.pdf #Autism #shorts
PLY agreement with Warner Bros.Interactive Entertainment
PlaySide Studios (ASX:PLY) announces the signing of a multi-game license agreement with Warner Bros. Interactive Entertainment to provide PLY with a highly recognisable intellectual property under license to develop two PC/Console game titles https://wcsecure.weblink.com.au/pdf/PLY/02753821.pdf #
TAH awarded a 20-year Victorian Wagering and Betting Licence
Tabcorp Holdings (ASX:TAH) has been awarded a 20-year Wagering and Betting Licence by the Victorian Government. The agreement removes Tabcorp’s Victorian Racing Industry joint venture and industry funding obligations | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231218/pdf/05ynsb3wkg0b7y.pdf #Victoria #shorts
SRJ Signs Global Collaboration Agreement with Air Control Entech
SRJ Technologies Group (ASX:SRJ) signed a three-year Global Collaboration Agreement with UK-based specialised advanced robotic inspector Air Control Entech. The agreement creates a framework to develop new technologies for the energy sector and expand the global reach of both entities | https://announcements.asx.com.au/asxpdf/20231215/pdf/05ylfc2s55032r.pdf #UK #shorts
BOT successful completion of human factors validation study
Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) announces that the Company has successfully completed the planned human factors validation study assessing the revised Instructions for Use for Sofpironium Bromide gel https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02753854-6A1186430 #shorts
AGN on track for Phase 2 trials during CY24
Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts